吉西他滨联合顺铂治疗非小细胞肺癌临床观察  

Gemcitabine and Cisplatin in the Treatment of Nonsmall Cell Lung Cancer : A Clinical Study

作　　者：王大鹏[1] 徐钟玲[1] 张伟[1] 张程[1] 刘晶[1] 

机构地区：[1]齐齐哈尔医学院附属肿瘤医院化疗科,黑龙江齐齐哈尔161002

出　　处：《中国现代医生》2009年第25期31-32,共2页China Modern Doctor

摘　　要：目的观察吉西他滨与顺铂联合化疗对非小细胞肺癌的疗效和不良反应。方法吉西他滨1000mg/m2第1、8天静脉滴注并联合顺铂治疗非小细胞肺癌50例,3周为1个治疗周期,6个周期后评价疗效和毒副作用,随访缓解期和生存期。结果50例均化疗4个周期以上,其中完全缓解(CR)2例,部分缓解(PR)21例,稳定(SD)22例,进展(PD)5例,缓解率(CR/PR)46%,中位疾病进展时间(TTP)为6.1个月,中位生存期12.2个月,1年生存率52.3%。中位缓解期9个月,中位生存期14个月。主要不良反应为骨髓抑制和胃肠道反应,Ⅲ～Ⅳ度白细胞减少发生率为10.59%,Ⅲ～Ⅳ度血小板减少发生率为2.6%;Ⅲ、Ⅳ度恶心、呕吐为1.46%。结论吉西他滨联合顺铂治疗非小细胞肺癌具有较好的疗效,且不良反应轻,患者可耐受。Objective To observe the efficacy and adverse reactions of Gemcitabine and Cisplatin combination chemotherapy for nonsmall cell lung cancer. Methods Gemcitabine（ 1000 mg/m^2,infusion at 1 and 8 days）and Cisplatin combined was used in the treatment of nonsmall cell lung cancer in 50 cases,with 3 weeks as a treatment cycle,tile efficacy and side effects after 6 cycles were evaluated,and the periods of remission and survival were followed up. Results Fifty cases received chemotherapy for more than 4 cycles,in which 2 cases were of CR,21 of PR,22 of SD and 5 of PD. The remission rate（CR/PR）was 46%. The median time of disease progression（TTP）was 6.1 months. The median survival time was 12.2 months. 1-year survival rate was 52.3%. The median remission was 9 months. The median survival time was 14 months. The main side effects was bone marrow suppression and gastrointestinal reactions. The incidence of Ⅲ-Ⅳ degree of leucopenia was 10.59%. The incidence of Ⅲ-Ⅳ degree of thrombocytopenia was 2.6%. The incidence of Ⅲ-Ⅳ degree of nausea and vomiting was 1.46%. Conclusion Gemcitabine and Cisplatin in the treatment of nonsmall cell lung cancer have better effectiveness and slight side effects which the patients can tolerate.

关 键 词：非小细胞肺癌 吉西他滨 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]